Search Results

Fluocinonide 500 mg  | 100.00%

TargetMol

Fluocinonide (Vanos) is an effective glucocorticoid steroid, utilized in the treatment as the skin disorders anti-inflammatory agent.

More Information Supplier Page

Fluocinonide 100 mg  | 100.00%

TargetMol

Fluocinonide (Vanos) is an effective glucocorticoid steroid, utilized in the treatment as the skin disorders anti-inflammatory agent.

More Information Supplier Page

Tenatoprazole 25 mg  | Purity Not Available

TargetMol

Tenatoprazole, a prodrug of the proton pump inhibitor (PPI) class, can inhibit proton transport (IC50: 3.2 μM).

More Information Supplier Page

Tenatoprazole 50 mg  | Purity Not Available

TargetMol

Tenatoprazole, a prodrug of the proton pump inhibitor (PPI) class, can inhibit proton transport (IC50: 3.2 μM).

More Information Supplier Page

A-1331852 5 mg  | 98.54%

TargetMol

A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.

More Information Supplier Page

A-1331852 25 mg  | 98.54%

TargetMol

A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.

More Information Supplier Page

Lomibuvir 5 mg  | 100.00%

TargetMol

Lomibuvir (VX-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo -initiated RNA synthesis [1].

More Information Supplier Page

Lomibuvir 50 mg  | 100.00%

TargetMol

Lomibuvir (VX-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo -initiated RNA synthesis [1].

More Information Supplier Page

Lomibuvir 25 mg  | 100.00%

TargetMol

Lomibuvir (VX-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo -initiated RNA synthesis [1].

More Information Supplier Page

Lomibuvir 10 mg  | 100.00%

TargetMol

Lomibuvir (VX-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo -initiated RNA synthesis [1].

More Information Supplier Page